Patient characteristics and clinical outcomes
| UPN . | Recip. age, y . | Donor age, y . | Sex, M/F . | Disease, status . | HLA typing . | Prep. reg. . | GVHD prop. reg. . | Graft source . | CMV status, D/R . | CMV react., Y/N . | Grade II-IV aGVHD to day +100, Y/N (day) . | Grade III-IV aGVHD to day +100, Y/N (day) . | Late aGVHD (day) . | Systemic aGVHD Tx . | Mild cGVHD, Y/N . | Mod/ Sev cGVHD, Y/N . | Systemic cGVHD Tx through day 365 . | Non-CMV infections . | Relapse Y/N, day post-Tx . | Alive day 365 post-Tx, Y/N (day of death) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 001-001 | 46 | 24 | M | AML, CR2 | A: 01/03; B: 08/52 | Cw: 1202*/0701; DRB1: 0301/0404* Recip. Cw: 1216 | Bu/ Cy | CNI/ MTX/ AB | PBSC | +/+ | Y | N | N | Y (220) | Steroids | N | N | N | Bacteremia | N | Y |
| 001-002 | 61 | 20 | F | AML, CR1 | A: 02/68; B: 18*/27* Recip. B: 08 | Cw: 0701/0704; DRB1: 1104/1501 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/− | N | N | N | N | N | Y | N | Short-course steroids | None | N | Y |
| 001-004 | 74 | 33 | F | AML, CR2 | A: 03/68; B: 07/18 | Cw: 0701*/0702; DRB1: 1401/1501* Recip. Cw: 0501 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/+ | Y | N | N | N | N | N | N | N | Bacteremia, parainflu. | Y, day +98 | N (121) |
| 001-005 | 59 | 19 | F | MDS → AML | A: 01/29; B: 08/44 | Cw: 0701/1601; DRB1: 0301/0701 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/− | N | N | N | N | N | N | Y | Steroids, siro. | Rhinovirus | N | Y |
| 001-006 | 43 | 21 | M | Biphen. Ph+ leukemia, CR1 | A: 03/11; B: 07/35 | Cw: 0401/0702; DRB1: 0101/1501 | TBI/ Cy | CNI/ MTX/ AB | PBSC | −/+ | N | N | N | N | N | N | Y | Steroids, cyclo. | None | N | Y |
| 001-007 | 46 | 45 | M | ALL, CR1 | A: 01/24*; B: 08/18* Recip. A: 26 | Cw: 0701/1203; DRB1: 0701/1104 | TBI/ Cy | CNI/ MTX/ AB | PBSC | +/+ | N | N | N | N | N | N | N | N | None | Y, day +121 | N (147) |
| 001-008 | 39 | 36 | M | AML, CR1 | A: 24/32; B: 27/40 | C: 0102/0202; DRB1: 0101/1601 | Bu/ Cy | CNI/ MTX/ AB | PBSC | +/+ | Y | Y (84) | Y | N | Steroids | N | Y | Steroids, ritux. | None | N | Y |
| 001-009 | 40 | 27 | M | CML, EMD | A: 02/24*; B: 14/45* Recip. A: 68 | Cw: 0802/1601; DRB1: 1001/1303 | Bu/ Cy | CNI/ MTX/ AB | PBSC | −/+ | Y | N, did develop grade I skin (49) | N | N | Steroids | N | Y | Steroids, cyclo., MMF | None | N | Y |
| 002-001 | 22 | 27 | F | ALL, CR3 | A: 02/68; B: 40/51 | Cw: 0304/1402; DRB1: 0401/1101 | TBI/ Cy | CNI/ MTX/ AB | BM | +/+ | N | N | N | N | N | Y | N | N | None | N | Y |
| 002-002 | 17 | 30 | F | ALL, IF | A: 02/03; B: 07/39 | Cw: 0701/0702; DRB1: 1401*/1303* Recip. DRB1: 1001 | TBI/ Cy | CNI/ MTX/ AB | BM | −/+ | Y | Y (29) | N | N | Steroids | N | Y | Steroids, cyclo. | Cellulitis, BK virus, LPD | N | Y |
| 003-001 | 30 | 40 | M | ALL, PIF | A: 02/02; B: 07/49 | Cw: 0701/0702; DRB1: 0401/0405 | Bu/ Cy | CNI/ MTX | PBSC | −/+ | N | N | N | N | N | Y | N | N | Y | Y, day +562 | Y |
| 003-002 | 35 | 45 | F | MF | A: 23/30*; B: 07/78* Recip. A: 33 | Cw: 0702/1601; DRB1: 0701/0901 | Bu/ Cy | CNI/ MTX | PBSC | +/− | Y | Y (48) | N | N | Steroids | N | Y | Steroids, tacro. | N | N | Y |
| 003-003 | 66 | 19 | M | MDS | A: 02; B: 15/44 | Cw: 0304/0501; DRB1: 0401 | Flu/ Mel | CNI/ MTX | PBSC | +/+ | N | Y (35) | Y (35) | N | Steroids inflix. | N | N | N | Y | N | Y |
| 003-004 | 48 | 25 | F | CP CML, TKI R/I | A: 01/29; B: 08/44 | Cw: 0501*/0701; DRB1: 0301/1201* Recip. Cw: 0102 | Bu/ Cy | CNI/ MTX | PBSC | +/− | N | Y (11) | Y (11) | N/A | Steroids inflix. | N/A | N/A | N/A | N | N | N (46) |
| 003-005 | 64 | 19 | F | ALL, CR2 | A: 02; B: 07/18 | Cw: 0501/0702; DRB1: 0301/1501 | TBI/ Cy | CNI/ MTX | PBSC | +/− | Y | N | N | N/A | N | N/A | N/A | N/A | N | N | N (80) |
| 003-006 | 41 | 55 | M | MDS | A: 02/03; B: 44*/40* Recip. B: 39 | Cw: 0304/0501; DRB1: 0403/1302 | Bu/ Cy/ ATG | CNI/ MTX | PBSC | +/− | N | Y (44) | Y (44) | N | Steroids inflix. | N/A | N/A | N/A | N | N | N (95) |
| 004-001 | 12 | 29 | M | ALL, CR1 | A: 02/11; B: 15/44 | Cw: 0304/1601; DRB1: 0401/0701 | TBI/ Cy/ VP16 | CNI/ MTX | BM | −/+ | N | N | N | N | N | N | N | N | N | N | Y |
| UPN . | Recip. age, y . | Donor age, y . | Sex, M/F . | Disease, status . | HLA typing . | Prep. reg. . | GVHD prop. reg. . | Graft source . | CMV status, D/R . | CMV react., Y/N . | Grade II-IV aGVHD to day +100, Y/N (day) . | Grade III-IV aGVHD to day +100, Y/N (day) . | Late aGVHD (day) . | Systemic aGVHD Tx . | Mild cGVHD, Y/N . | Mod/ Sev cGVHD, Y/N . | Systemic cGVHD Tx through day 365 . | Non-CMV infections . | Relapse Y/N, day post-Tx . | Alive day 365 post-Tx, Y/N (day of death) . | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 001-001 | 46 | 24 | M | AML, CR2 | A: 01/03; B: 08/52 | Cw: 1202*/0701; DRB1: 0301/0404* Recip. Cw: 1216 | Bu/ Cy | CNI/ MTX/ AB | PBSC | +/+ | Y | N | N | Y (220) | Steroids | N | N | N | Bacteremia | N | Y |
| 001-002 | 61 | 20 | F | AML, CR1 | A: 02/68; B: 18*/27* Recip. B: 08 | Cw: 0701/0704; DRB1: 1104/1501 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/− | N | N | N | N | N | Y | N | Short-course steroids | None | N | Y |
| 001-004 | 74 | 33 | F | AML, CR2 | A: 03/68; B: 07/18 | Cw: 0701*/0702; DRB1: 1401/1501* Recip. Cw: 0501 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/+ | Y | N | N | N | N | N | N | N | Bacteremia, parainflu. | Y, day +98 | N (121) |
| 001-005 | 59 | 19 | F | MDS → AML | A: 01/29; B: 08/44 | Cw: 0701/1601; DRB1: 0301/0701 | Flu/ Mel | CNI/ MTX/ AB | PBSC | −/− | N | N | N | N | N | N | Y | Steroids, siro. | Rhinovirus | N | Y |
| 001-006 | 43 | 21 | M | Biphen. Ph+ leukemia, CR1 | A: 03/11; B: 07/35 | Cw: 0401/0702; DRB1: 0101/1501 | TBI/ Cy | CNI/ MTX/ AB | PBSC | −/+ | N | N | N | N | N | N | Y | Steroids, cyclo. | None | N | Y |
| 001-007 | 46 | 45 | M | ALL, CR1 | A: 01/24*; B: 08/18* Recip. A: 26 | Cw: 0701/1203; DRB1: 0701/1104 | TBI/ Cy | CNI/ MTX/ AB | PBSC | +/+ | N | N | N | N | N | N | N | N | None | Y, day +121 | N (147) |
| 001-008 | 39 | 36 | M | AML, CR1 | A: 24/32; B: 27/40 | C: 0102/0202; DRB1: 0101/1601 | Bu/ Cy | CNI/ MTX/ AB | PBSC | +/+ | Y | Y (84) | Y | N | Steroids | N | Y | Steroids, ritux. | None | N | Y |
| 001-009 | 40 | 27 | M | CML, EMD | A: 02/24*; B: 14/45* Recip. A: 68 | Cw: 0802/1601; DRB1: 1001/1303 | Bu/ Cy | CNI/ MTX/ AB | PBSC | −/+ | Y | N, did develop grade I skin (49) | N | N | Steroids | N | Y | Steroids, cyclo., MMF | None | N | Y |
| 002-001 | 22 | 27 | F | ALL, CR3 | A: 02/68; B: 40/51 | Cw: 0304/1402; DRB1: 0401/1101 | TBI/ Cy | CNI/ MTX/ AB | BM | +/+ | N | N | N | N | N | Y | N | N | None | N | Y |
| 002-002 | 17 | 30 | F | ALL, IF | A: 02/03; B: 07/39 | Cw: 0701/0702; DRB1: 1401*/1303* Recip. DRB1: 1001 | TBI/ Cy | CNI/ MTX/ AB | BM | −/+ | Y | Y (29) | N | N | Steroids | N | Y | Steroids, cyclo. | Cellulitis, BK virus, LPD | N | Y |
| 003-001 | 30 | 40 | M | ALL, PIF | A: 02/02; B: 07/49 | Cw: 0701/0702; DRB1: 0401/0405 | Bu/ Cy | CNI/ MTX | PBSC | −/+ | N | N | N | N | N | Y | N | N | Y | Y, day +562 | Y |
| 003-002 | 35 | 45 | F | MF | A: 23/30*; B: 07/78* Recip. A: 33 | Cw: 0702/1601; DRB1: 0701/0901 | Bu/ Cy | CNI/ MTX | PBSC | +/− | Y | Y (48) | N | N | Steroids | N | Y | Steroids, tacro. | N | N | Y |
| 003-003 | 66 | 19 | M | MDS | A: 02; B: 15/44 | Cw: 0304/0501; DRB1: 0401 | Flu/ Mel | CNI/ MTX | PBSC | +/+ | N | Y (35) | Y (35) | N | Steroids inflix. | N | N | N | Y | N | Y |
| 003-004 | 48 | 25 | F | CP CML, TKI R/I | A: 01/29; B: 08/44 | Cw: 0501*/0701; DRB1: 0301/1201* Recip. Cw: 0102 | Bu/ Cy | CNI/ MTX | PBSC | +/− | N | Y (11) | Y (11) | N/A | Steroids inflix. | N/A | N/A | N/A | N | N | N (46) |
| 003-005 | 64 | 19 | F | ALL, CR2 | A: 02; B: 07/18 | Cw: 0501/0702; DRB1: 0301/1501 | TBI/ Cy | CNI/ MTX | PBSC | +/− | Y | N | N | N/A | N | N/A | N/A | N/A | N | N | N (80) |
| 003-006 | 41 | 55 | M | MDS | A: 02/03; B: 44*/40* Recip. B: 39 | Cw: 0304/0501; DRB1: 0403/1302 | Bu/ Cy/ ATG | CNI/ MTX | PBSC | +/− | N | Y (44) | Y (44) | N | Steroids inflix. | N/A | N/A | N/A | N | N | N (95) |
| 004-001 | 12 | 29 | M | ALL, CR1 | A: 02/11; B: 15/44 | Cw: 0304/1601; DRB1: 0401/0701 | TBI/ Cy/ VP16 | CNI/ MTX | BM | −/+ | N | N | N | N | N | N | N | N | N | N | Y |
AB, abatacept; aGVHD, acute GVHD; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, antithymocyte globulin; Biphen., biphenotypic; BM, bone marrow; Bu, busulfan; cGVHD, chronic GVHD; CML, chronic myelogenous leukemia; CNI, calcineurin inhibitor; CP, chronic phase; CR, complete remission; Cy, cyclophosphamide; cyclo., cyclosporine; D/R, donor/recipient; EMD, extramedullary disease; F, female; Flu, fludarabine; GVHD, graft-versus-host disease; IF, induction failure; inflix., infliximab; LPD, lymphoproliferative disease; M, male; MDS, myelodysplastic syndrome; Mel, melphalan; MF, myelofibrosis; MMF, mycophenolate mofetil; Mod/Sev, moderate/severe; MTX, methotrexate; N, no; N/A, not applicable; parainflu., parainfluenza; PBSC, peripheral blood stem cell; Ph+, Philadelphia chromosome positive; PIF, primary induction failure; Prep. reg., preparative regimen; prop. reg., prophylaxis regimen; react., reactivation; Recip., recipient; R/I, resistant/intolerant; ritux., rituximab; siro., sirolimus; tacro., tacrolimus; TBI, total body irradiation; TKI, receptor-tyrosine kinase inhibitor; Tx, treatment; UPN, unidentified patient number; VP16, etoposide; Y, yes.